Follow the accumulating evidence and observations that shape our view of health policy and obesity
June 19, 2025 — In drug therapy for obesity, all of the excitement about GLP-1s and now amylin analogs has focused on regulation of eating behaviors. But, in fact, this is just one part of the process for regulating metabolic function and adiposity. Until now, we have seen little success in developing safe and effective medicines that alter the […]
June 18, 2025 — “Oops.” It seems that Novo Nordisk has left a door wide open for generic semaglutide to enter the market in Canada next year. This news spilled out of an interview with the CEO of a generic pharmaceuticals company, Richard Saynor of Sandoz. He told Endpoints News that his company had filed for a generic semaglutide […]
June 17, 2025 — While much of the public has focused on the remarkable effects of GLP-1 agonists for many people living with obesity, an even more remarkable story has largely escaped notice. In March, FDA approved the first ever treatment for Prader-Willi syndrome. This drug, an extended-release form of diazoxide choline, is transforming the lives of families of […]
June 16, 2025 — Reject the binary. This cry is a response to simplistic, dichotomous thinking that seems to be ruling the day in so many contexts right now. It’s taking us on quite a number of dead-end journeys. One of these is the false dichotomy that suggests we must choose between providing care for obesity or for disordered […]
June 15, 2025 — The previously unquestioned American leadership in science is evaporating. Groundbreaking medical research is stopping abruptly. Research institutes at NIH are disappearing. As this unfolds, the response of many people in supposed roles of scientific leadership has been to duck and take cover. Tell us when it’s over and we can get back to work. Yes, […]
June 14, 2025 — As the upcoming Scientific Sessions for the American Diabetes Association draws closer, the drumbeat for amycretin as a promising new therapy for obesity is growing louder. At the meeting, Novo Nordisk plans to present two different studies to strengthen the case for this novel dual agonist. It targets both GLP-1 and amylin receptors. Then yesterday […]
June 13, 2025 — Thoughtful reporting by Jackie Snow in the New York Times prompts us to wonder about the possibility of a “contagion effect” from GLP-1s in families. When a parent receives highly effective treatment for obesity, what might the effect be on other family members? Of course, any answers to this question come from anecdotal observations. They […]
June 12, 2025 — It is undeniable that obesity is a complex, chronic disease. When we gather people from all over the world who understand obesity, this is the number one thing everyone can agree upon. And yet, when we sit down to talk about models for health systems delivering obesity care, it is more likely that folks who […]
June 11, 2025 — Honestly, we cannot figure out why this basic fact of obesity treatment seems so hard for so many people to grasp. New, advanced medicines for obesity don’t work well when a person doesn’t take them. A new study in Obesity drives this point home. Hamlet Gasoyan and colleagues found that discontinuations and sub-optimal dosing of […]
June 10, 2025 — Yesterday, Metsera presented investors with topline data from phase one studies of a new amylin analog for obesity that promises monthly dosing. This is an early stage drug known only by its code name – MET-233i. Metsera is a young biotech company, founded in 2022. The big news here: 8.4% placebo-subtracted weight loss after 36 […]
